Streetbeat News

Products Services

AZTR

Azitra has initiated a Phase 1b clinical trial for ATR-12, targeting Netherton Syndrome. The trial will involve 12 adults over 14 days, with interim safety data expected in early 2025 and full results in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:31 pm

WATT

Energous Corporation (NASDAQ:WATT) has received full FCC certification for its 2W PowerBridge transmitter system, marking it as the first certified transmitter at this power level. This system enhances wireless power networks by providing up to 8W EIRP, improving supply chain visibility and enabling continuous wireless power and real-time data for connected devices.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:31 pm

ALUR

Allurion Technologies has announced a study showing an average weight reduction of 13.7% at one year with its Allurion Program, an increase from 10.5% at four months. The study highlights the effectiveness of ongoing virtual guidance and support in sustaining and increasing weight loss.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:29 pm

BRK

CMG

VST

WYNN

On CNBC's 'Halftime Report Final Trades,' several stocks were highlighted: Berkshire Hathaway hit an all-time high, Vistra Corp. posted better-than-expected earnings, Wynn Resorts reported downbeat results, and Chipotle announced a new menu item. Stock movements were mixed.

Portfolio Pulse from Avi Kapoor

August 28, 2024 | 12:20 pm

AMBA

ANF

VRAX

Virax Biolabs, Ambarella, and Abercrombie & Fitch experienced significant stock movements. Virax Biolabs surged 35% due to a new distribution agreement for Mpox virus detection kits. Ambarella rose 23% after surpassing Q2 earnings expectations. Abercrombie & Fitch fell 10% amid uncertain market conditions.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:10 pm

HLIT

Harmonic (NASDAQ:HLIT) partners with Globo to transition its playout workflow to the cloud, enhancing efficiency and reducing costs.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:09 pm

ARQT

Arcutis Biotherapeutics reported positive long-term results from its INTEGUMENT-OLE study, demonstrating the efficacy and safety of Roflumilast Cream 0.05% for treating mild to moderate atopic dermatitis in children. The company plans to submit a supplemental New Drug Application (sNDA) to the FDA in Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:07 pm

GMGI

Golden Matrix Group is expanding its presence in the iGaming market by applying for a license in New Jersey, obtaining a license in Bulgaria, and targeting Brazil's $20 billion market through its subsidiary, Meridianbet.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:06 pm

VXRT

Vaxart has announced promising preclinical data for its mucosal vaccine technology, which shows potential in treating HPV-related tumors. The vaccine stimulated an immune response, reduced tumor size, and increased survival in an animal model, indicating potential for non-invasive treatment of HPV-related cervical dysplasia.

Portfolio Pulse from Benzinga Newsdesk

August 28, 2024 | 12:04 pm

FL

Foot Locker reported a Q2 adjusted EPS loss of 5 cents, beating expectations, and sales of $1.896 billion, also surpassing estimates. Despite positive sales growth and margin expansion, the stock fell 8.11% premarket due to store closures and a cautious outlook.

Portfolio Pulse from Anusuya Lahiri

August 28, 2024 | 12:03 pm